Acceleron Pharma Inc (XLRN) Q3 2019 Earnings Call Transcript
XLRN earnings call for the period ending .
Acceleron Pharma
XLRN
XLRN
$40.97
-$2.02
-4.7%
BATS BZX Real Time Price as of November 15, 2019, 4:00 p.m. EST
View Interactive XLRN Charts
CONTROLADORA VUELA SPON ADR REPR 10 CPOS
News & Analysis: Acceleron Pharma
Acceleron's Q3 Results Focus Squarely on Its Celgene Collaboration
The biotech's Q3 results and future fortunes hinge on approvals for the blood-disease drug it licensed to Celgene.
Here’s Why Acceleron Pharma Stock Fell 12% in September
The biotech’s pipeline is shrinking, but investors should focus on what will drive near-term value.
Don't Dismiss Acceleron Despite Its Recent Clinical Setback
The small pharma company had disappointing results from its second phase clinical trials. Here’s why it’s too soon to throw in the towel.
5 Biggest New Drug Approvals Potentially on the Way in 2019
FDA approvals for these drugs could translate to billions of dollars for a few companies.
Acceleron Pharma Inc (XLRN) Q2 2019 Earnings Call Transcript
XLRN earnings call for the period ending June 30, 2019.
Acceleron Pharma Inc (XLRN) Q2 2019 Earnings Call Transcript
XLRN earnings call for the period ending June 30, 2019.
What You'll Want to Know About Acceleron Pharma's Q2 Update
The big story for Acceleron: waiting on good news for luspatercept.
Acceleron Pharma Inc (XLRN) Q1 2019 Earnings Call Transcript
XLRN earnings call for the period ending March 31, 2019.
Acceleron Pharma (XLRN) Q4 2018 Earnings Conference Call Transcript
SQ earnings call for the period ending December 31, 2018
